<DOC>
	<DOCNO>NCT02944708</DOCNO>
	<brief_summary>The purpose study examine efficacy maintenance chemotherapy treatment metastatic nasopharyngeal carcinoma . Participants randomize 3 arm . Arm 1 , control group , participant receive 4-8 cycle conventional chemotherapy ; arm 2 , participant receive 6 cycle maintenance chemotherapy conventional chemotherapy ; arm 3 , experiment arm , conventional chemotherapy , participant receive maintenance chemotherapy disease progression intolerable toxicity .</brief_summary>
	<brief_title>Trial Evaluating Maintenance Chemotherapy Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>This phase 3 randomized clinical trial determine efficacy maintenance chemotherapy treatment metastatic chemotherapy deliver . Participants randomize 3 arm . Arm 1 ( control group ) , participant receive conventional chemotherapy ; arm 2 ( experimental group ) , participant receive 6 cycle maintenance chemotherapy conventional chemotherapy ; arm 3 ( experimental group ) , conventional chemotherapy , participant receive maintenance chemotherapy disease progression intolerable toxicity . Participants 3 arm receive similar conventional chemotherapy . Four eight cycle conventional chemotherapy platinum-based regimen prefer . Maintenance chemotherapy use one regimen : S1 ( 40mg , twice day 14 day , every 3 week ) , capecitabine ( 1000mg/m^2 , twice day 14 day , every 3 week ) Tegafur-uracil ( 100mg/m^2 , q8h , 14 day , every 3 week ) . The response treatment evaluate accord RECIST criterion . Adverse event document accord CTCAE v4.03 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Age ≥ 18 ≤ 70 year Histologically confirm nasopharyngeal carcinoma , WHO ( World Health Organization ) classification II/III With distant metastasis With measurable lesion detect image study Achieving PR ( partial response ) 4 cycle conventional chemotherapy Life expectancy ≥ 6 month ECOG ( Eastern Cooperative Oncology Group ) : 01 , significant active concurrent medical illness Adequate laboratory value within 30 dyas enrollment study define follow : N &gt; 2000/mm^3 ; PLT ( platelet count ) &gt; 100,000/mm^3 ; total bilirubin &lt; 1.5mg/dl ; AST ( aspartate aminotransferase ) /ALT ( alanine aminotransferase ) &lt; 1.5 ULN ( upper limit normal ) ; SCr ( serum creatinine ) &lt; 1.5mg/dl ; CCR ( creatinine clearance rate ) &gt; 60ml/min Willing accept adequate contraception woman childbearing potential Ability understand character individual consequence clinical trial Willing sign write informed consent ; Informed consent must sign enrollment trial Received previous treatment metastatic disease Pregnant lactate woman A diagnosis malignancy CIS ( carcinoma situ ) cervix , BCC ( basal cell carcinoma ) SCC ( squamous cell carcinoma ) skin within past 5 year Refusal patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>maintenance chemotherapy</keyword>
</DOC>